rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
rs121913530
|
|
|
0.880 |
GeneticVariation |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis demonstrated that the two common variations (rs8034191 and rs1051730) at 15q25 are a risk factor associated with increased LC susceptibility, but these associations vary in different ethnic populations.
|
24254305 |
2014 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The nicotinic acetylcholine receptor polymorphism (rs1051730) on chromosome 15q25 is associated with major tobacco-related diseases in the general population with additional increased risk of COPD as well as lung cancer.
|
23061658 |
2012 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We observed a significant association between lung cancer and rs1051730 in pooled population by using allele (OR = 1.30, 95% CI = 1.27-1.34, P < 0.0001), dominant (OR = 1.41, 95% CI = 1.29-1.55, P < 0.0001), recessive (OR = 1.53, 95% CI = 1.42-1.65, P < 0.0001) and additive (OR = 1.75, 95% CI = 1.61-1.90, P < 0.0001) models.
|
26508385 |
2015 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, the authors apply a novel method for mediation analysis, allowing for gene-environment interaction, to a lung cancer case-control study (1992-2004) conducted at Massachusetts General Hospital using 2 single nucleotide polymorphisms, rs8034191 and rs1051730, on 15q25.1.
|
22306564 |
2012 |
rs1051730
|
|
T |
0.800 |
GeneticVariation |
GWASCAT |
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.
|
30104567 |
2018 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We also investigated the relationship between the rs1051730 SNP in an intron of the CHRNA3 gene (the polymorphism most significantly associated with lung cancer risk and smoking behavior) and TSD.
|
21645942 |
2011 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition, the A alleles in CHRNA3 rs1051730 and CHRNA5 rs16969968 were associated with the risk for LC (OR = 1.66, P = 0.07 and OR = 1.57, P = 0.1, respectively) and for COPD (OR = 2.04, P = 0.01 and OR = 1.91, P = 0.02, respectively).
|
29993116 |
2018 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our findings demonstrated that CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191-T allele might be risk-conferring factors for the development of lung cancer in Caucasians, but not in East-Asians.
|
22701590 |
2012 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The risk of lung cancer was more than fivefold higher among those subjects who had both a family history of lung cancer and two copies of high-risk alleles rs8034191 (odds ratio [OR] = 7.20, 95% confidence interval [CI] = 2.21 to 23.37) or rs1051730 (OR = 5.67, CI = 2.21 to 14.60, both of which were located in the 15q24-25.1 locus, than among control subjects.
|
18780872 |
2008 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Similarly, neither CHRNA3 rs8034191 nor rs1051730 were associated with lung cancer risk.
|
20068085 |
2010 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We used urinary biomarkers to test whether two linked lung cancer risk variants in CHRNA3 (rs1051730) and CHRNA5 (rs16969968) are associated with intensity of smoking and exposure to a tobacco-specific carcinogenic nitrosamine per cigarette dose.
|
19010884 |
2008 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We found that 2 risk single nucleotide polymorphisms reported in the lung cancer GWA studies-rs8034191: A>G and rs1051730: G>A, located in this 15q24-25.1 region-were not associated with risk of pancreatic cancer.
|
21697764 |
2011 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the chr15q25.1 region spanning the nicotinic receptors CHRNA3 and CHRNA5, we identified multiple SNPs associated with CPD (p<10(-3)), including rs1051730, which has been associated with nicotine dependence, smoking intensity and lung cancer risk.
|
19247474 |
2009 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The increase in cotinine levels indicated an increased risk of lung cancer with each additional copy of the rs1051730-rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42).
|
22534784 |
2012 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We further showed that these two genetic variants on 15q24-25.1 independently influence lung cancer risk (rs1051730: P = 4.42 x 10(-11); OR, 1.60; 95% CI, 1.46-1.74; rs481134: P = 7.01 x 10(-4); OR, 0.81; 95% CI, 0.72-0.92).
|
20395203 |
2010 |
rs1051730
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Smoking behavior and COPD are mediators of the association between the single nucleotide polymorphism (SNP) rs1051730 and the risk of lung cancer.
|
20564069 |
2010 |